Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-22
2008-01-22
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211100, C514S211120, C540S548000, C540S550000
Reexamination Certificate
active
07320973
ABSTRACT:
The present invention provides dihydrodiaryloxazepine derivative represented by the following formula [1], analogs thereof and pharmaceutical compositions containing them. Those compounds have an excellent effect of improving functional diseases of gastrointestinal tracts
REFERENCES:
patent: 6127361 (2000-10-01), Tanaka et al.
patent: 6436922 (2002-08-01), Tanaka et al.
patent: 6528504 (2003-03-01), Sakata et al.
patent: 6562808 (2003-05-01), Sakata et al.
patent: 0 404 359 (1990-12-01), None
patent: 0 889 043 (1999-01-01), None
patent: 1 020 466 (2000-07-01), None
patent: 2000-351778 (2000-12-01), None
patent: WO97/33885 (1997-09-01), None
patent: WO99/12925 (1999-03-01), None
patent: WO00/40570 (2000-07-01), None
patent: WO01/17980 (2001-03-01), None
patent: WO02/48120 (2002-06-01), None
U.S. Appl. No. 10/724,179, filed Dec. 1, 2003, Sakata et al.
U.S. Appl. No. 10/086,781, filed Mar. 4, 2002, Sekiyama et al.
P. Quinn et al, “UK-84,149: A Potent and Gut-Selective Spasmolytic in the Anaesthetised Dog”,British Journal of Pharmacology, 1994, vol. 112, Proceedings Supplement, 573P.
R.M. Wallis et al, “UK-84,149: A Novel Gut-Selective Spasmolytic with Calcium Antagonist Activity”,British Journal of Pharmacology, 1994, vol. 112, Proceedings Supplement, 574P.
F. Narducci et al, “Nifedipine Reduces the Colonic Motor Response to Eating in Patients with the Irritable Colon Syndrome”,The American Journal of Gastroenterology, May 1985, vol. 80, No. 5, pp. 317-319.
A. Prior et al, “Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome”,Gut, 1987, vol. 28, pp. 1609-1612.
J. Clin. Psychiatry, Sep. 1987, vol. 48, No. 9, pp. 388-389.
F. De Ponti et al, “Calcium-Channel Blockers and Gastrointestinal Motility: Basic and Clinical Aspects”,Pharmac. Ther., 1993, vol. 60, pp. 121-148.
H. L. Yale et al, “Novel Polycyclic Heterocycles. II. Derivatives of 5,11-Dihydrodibenz[b,e][1,4]oxazepine1”,J. Med. Chem., Sep. 1964, vol. 7, pp. 609-614.
G. J. Sanger et al, “Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT4receptor antagonist, SB-207266”,British Journal of Pharmacology, 2000, vol. 130, pp. 706-712.
K. Hara et al, “Antinociceptive Effects of Intrathecal L-Type Calcium Channel Blockers on Visceral and Somatic Stimuli in the Rat”,Anesth. Analg., 1998, vol. 87, pp. 382-387.
Ezaki Junko
Hirasawa Shigeo
Sakata Katsutoshi
Takahashi Kazuyoshi
Tokumasu Munetaka
Ajinomoto Co. Inc.
Coleman Brenda
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Dihydrodiaryloxazepine derivative and pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydrodiaryloxazepine derivative and pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydrodiaryloxazepine derivative and pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2753437